Objective: To probe into the long-term efficacy of subcutaneous specific immunotherapy in children with chronic allergic rhinosinusitis. Methods: Children aged from 5 to 14 years with chronic rhinosinusitis and skin prick test mite positive (+++) diagnosed in allergy clinic of Maternity and Child Healthcare Hospital of Hubei from Jun. 2015 to Jun. 2016 were extracted to be randomly divided into the control group and the observation group

with 30 cases in each group. The control group received routine treatment such as local glucocorticoids

antiallergic drugs

necessary antibiotics and nasal irrigation

while the observation group was given standardized mite allergen preparation for subcutaneous specific immunotherapy on the basis of routine treatment. Visual analogue scale (VAS) score and Lund-Kennedy nasal endoscopy score were used for evaluation in two groups before treatment and after treatment of 1

2 and 3 years. Results: There was no statistically significant difference in VAS score and Lund-Kennedy score between two groups before treatment (P>0.05). There was no significant difference in VAS score and Lund-Kennedy score in the control group before treatment and after treatment of 1

2 and 3 years (P>0.05). VAS score and Lund-Kennedy score decreased significantly after treatment of 1

2 and 3 years compared with those before treatment in the observation group (P<0.01)

and were significant lower than those of the control group during the same period (P<0.01). Conclusion: Subcutaneous specific immunotherapy can reduce the local inflammatory response in nasal cavity

prevent the recurrence of allergic chronic rhinosinusitis in children

improve the prognosis

and have stable long-term efficacy

which is a recommended treatment method.